Stephen Dilly Headshot Stephen Dilly, MBBS, PhD, President & CEO of Codexis, Inc.REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE)…
Meetings with Growth-Oriented Investors, September 29 to October 1, 2023MISSISSAUGA, Ontario, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc.…
CANACA Introduces New Flower Offerings and Infused Pre-roll LineupTORONTO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or…
SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation…
Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential…
This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as…
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and…
EDINBURGH and CAMBRIDGE, United Kingdom, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, continues…
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or…
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of…